Anti-CD3 recombinant antibody [UCH-T1^TM]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-CD3 recombinant antibody [UCH-T1^TM]
• Research fields: Cancer;Cell biology;Cell signaling and signal transduction;Immunology;Stem cell biology
• Clone: rUCH-T1
• Tool sub type: Primary antibody
• Class: Recombinant
• Conjugation: Unconjugated
• Reactivity: Human
• Host: Mouse
• Application: FACS ; WB
• Description: Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemia’s. Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains ( CD3gamma, CD3omega and 2X CD3epsilon), associates with the T cell antigen receptor (TCR). It is found on all mature human T lymphocytes, NK cells and some thymocytes. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction. This is a recombinant version of anti-CD3 UCH-T1 . UCH-T1 is considered a pan T-cell marker - it can be used for the detection of T cell populations in peripheral blood and lymph nodes and the categorisation of T versus B cell lymphomas and leukaemias. It reacts with the majority of peripheral blood T lymphocytes, a major proportion of thymocytes, the majority of T cell chronic lymphocytic leukaemia cells, Sezary leukaemias and approximately 70% of acute lymphoblastic leukaemias of T cell origin. It can also be used to study the role of CD3 in TCR signal transduction events. This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with UCHT1 being one of the first successful fusions.
• Immunogen: Human infant thymocytes and Sezary cells.
• Immunogen uniprot id: P04234
• Isotype: IgG1
• Additional notes: UCH-T1TM is a registered trademark of Cancer Research Technology, Limited. All rights reserved.

Target Details

• Target: CD3
• Target background: Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemia's.Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains ( CD3?, CD3d and 2X CD3), associates with the T cell antigen receptor (TCR). It is found on all mature human T lymphocytes, NK cells and some thymocytes. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction.This is a recombinant version of anti-CD3 UCH-T1. UCH-T1 is considered a pan T-cell marker - it can be used for the detection of T cell populations in peripheral blood and lymph nodes and the categorisation of T versus B cell lymphomas and leukaemia's. It reacts with the majority of peripheral blood T lymphocytes, a major proportion of thymocytes, the majority of T cell chronic lymphocytic leukaemia cells, Szary leukaemia's and approximately 70% of acute lymphoblastic leukaemia's of T cell origin. It can also be used to study the role of CD3 in TCR signal transduction events.This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with UCHT1 being one of the first successful fusions.

Applications

• Application: FACS ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS only
• Storage conditions: Store at -20 C frozen. Avoid repeated freeze / thaw cycles
• Shipping conditions: Dry ice

Related Tools

• Related tools: Anti-CD3 [UCH-T1™]

References

• Original hybridoma first published in: Beverley et al. 1981. Eur J Immunol. 11(4):329-34. PMID: 6788570.
• Distinctive Fn characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody.